AB Biotechnology Enhances Peptide QC with Shimadzu’s PPSQ Technology

AB Biotechnology, a GMP-licensed Contract Development and Manufacturing Organisation (CDMO), has taken a significant step forward in its peptide synthesis and quality control (QC) capabilities by integrating Shimadzu’s PPSQ protein sequencing system into its operations.

Clare Elliot and Rebecca Clowes - QC Scientists responsible for performing the peptide analysis using PPSQ. 

Specialising in the production of biological drug substances for both commercial and clinical use, AB Biotechnology is known for its emphasis on precision, quality, and innovation. The recent adoption of Shimadzu’s PPSQ system—featuring an Edman degradation unit combined with high-performance liquid chromatography (HPLC)—represents a strategic upgrade that supports these core values.

“The introduction of the PPSQ technology has allowed us to bring peptide sequencing fully in-house,” said Chris Mack, Quality Manager at AB Biotechnology. “This means greater control over timelines and quality standards, particularly in QC release testing for peptides manufactured at our facility.”

The move away from third-party providers has improved turnaround times and enhanced traceability and oversight, which are especially important in regulated environments. Beyond supporting internal manufacturing, AB Biotechnology is now offering peptide sequencing as a standalone service, responding to growing industry demand for high-quality, dependable peptide analysis.

“Our ability to deliver this service directly is a reflection of our broader commitment to continuous improvement,” Chris added. “It’s about giving our clients confidence that they’re working with a partner who understands the complexities of peptide development and who invests in the right tools to meet those challenges.”

The successful onboarding of the PPSQ system was the result of close collaboration with Shimadzu’s engineering and support teams, whose guidance ensured a smooth and effective setup. Their technical expertise played a vital role in optimising the system for AB Biotechnology’s specific workflows and requirements.

Looking ahead, AB Biotechnology is well-positioned to expand its capabilities further, continuing to offer high-quality, science-driven solutions to both new and existing partners. With Shimadzu’s PPSQ technology now integrated into its QC framework, the company reaffirms its role as a trusted, forward-thinking CDMO in the biologics space.